Zealand Pharma

Director's Dealing • Nov 23, 2011

Copenhagen, 2011-11-23 13:42 CET (GLOBE NEWSWIRE) -- Copenhagen, 23 November
2011 - Pursuant to the Danish Securities Trading Act, section 28a, Zealand
Pharma A/S, a Danish biopharmaceutical company dedicated to the discovery and
development of innovative peptide drugs, shall announce transactions in the
company's shares and related securities by executives and persons/companies
closely related to them. In this regard, Zealand Pharma announces the following
transactions:

Name: Dr. Alain Munoz

Reason: Member of the board

Issuer: Zealand Pharma A/S

Type Shares

ISIN code: DK0060257814

Transaction: Purchase

Trading date: 22 November 2011

Market: NASDAQ OMX Copenhagen

Amount: 3,500

Price: DKK 39

Market value: DKK 136,500

Name: Science and Business Management

Reason: Dr. Alain Munoz, member of the board of Zealand Pharma A/S, is CEO
and owner of Science and Business Management

---

Issuer: Zealand Pharma A/S

Type Shares

ISIN DK0060257814
code:

---

Transacti Purchase
on:

---

Trading 22 November 2011
date:

---

Market: NASDAQ OMX Copenhagen

Amount: 3,500

Price: DKK 39

Market DKK 136,500
value:

---

For further information, please contact:

David Horn Solomon, President and Chief Executive Officer

Tel: +45 2220 6300

Hanne Leth Hillman, Vice President for IR & Corporate Communication

Tel: +45 5060 3689

About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company
based in Copenhagen, Denmark with a mature and growing clinical pipeline of
innovative peptide based drugs. The company's lead product is Lyxumia®
(lixisenatide), a once-daily GLP-1 agonist licensed to Sanofi, which has
Lyxumia® in late-stage Phase III development for the treatment of type 2
diabetes. Zealand Pharma also has a collaboration with Boehringer Ingelheim
covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of
diabetes and obesity, and a licence agreement with Helsinn Healthcare on
elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy- and
radiotherapy-induced diarrhea.

Zealand Pharma specializes in the discovery, optimization and development of
novel peptide drugs with favorable therapeutic attributes, and all drug
candidates in its pipeline have been identified through the company's own drug
discovery activities. Zealand Pharma's products target disease areas where
existing treatments fail to adequately serve patient needs and where the market
potential for improved treatments through the use of peptide drugs is high. For
further information: www.zealandpharma.com.